Phreesia, Inc. $PHR Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its holdings in Phreesia, Inc. (NYSE:PHR) by 12.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 172,917 shares of the company’s stock after selling 24,931 shares during the quarter. Russell Investments Group Ltd.’s holdings in Phreesia were worth $4,921,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock valued at $67,606,000 after purchasing an additional 1,377,904 shares during the last quarter. American Century Companies Inc. increased its stake in Phreesia by 3,741.9% during the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock valued at $25,137,000 after purchasing an additional 957,842 shares in the last quarter. Nuveen LLC purchased a new position in shares of Phreesia in the first quarter worth $14,206,000. Champlain Investment Partners LLC lifted its stake in shares of Phreesia by 20.0% during the first quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock worth $75,312,000 after buying an additional 490,340 shares during the period. Finally, Park West Asset Management LLC grew its stake in Phreesia by 111.2% during the 1st quarter. Park West Asset Management LLC now owns 894,501 shares of the company’s stock valued at $22,863,000 after purchasing an additional 470,931 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Insider Activity at Phreesia

In other news, CFO Balaji Gandhi sold 4,183 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $97,380.24. Following the completion of the sale, the chief financial officer directly owned 99,125 shares in the company, valued at $2,307,630. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Evan Roberts sold 1,888 shares of the business’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $42,215.68. Following the transaction, the insider directly owned 724,949 shares in the company, valued at $16,209,859.64. This trade represents a 0.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 26,174 shares of company stock worth $603,835 in the last 90 days. 5.50% of the stock is owned by insiders.

Phreesia Stock Performance

NYSE:PHR opened at $20.26 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. The stock has a market capitalization of $1.21 billion, a PE ratio of -48.24 and a beta of 0.64. Phreesia, Inc. has a fifty-two week low of $18.55 and a fifty-two week high of $32.76. The company has a fifty day moving average of $22.09 and a two-hundred day moving average of $25.27.

Phreesia (NYSE:PHR) last released its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. During the same quarter last year, the business posted ($0.03) earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. As a group, research analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Mizuho initiated coverage on shares of Phreesia in a research note on Wednesday, August 27th. They set an “outperform” rating and a $36.00 price objective for the company. Raymond James Financial set a $33.00 target price on shares of Phreesia and gave the company an “outperform” rating in a research report on Friday, September 5th. JMP Securities upped their price target on shares of Phreesia from $30.00 to $34.00 and gave the company a “market outperform” rating in a report on Monday, September 8th. DA Davidson lifted their price objective on Phreesia from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Needham & Company LLC boosted their price objective on Phreesia from $29.00 to $35.00 and gave the company a “buy” rating in a report on Friday, September 5th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.86.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.